ALXN:NGS-Alexion Pharmaceuticals Inc.

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 115.32

Change

-4.36 (-3.64)%

Market Cap

USD 25.70B

Volume

1.81M

Yahoo Analyst Target

USD 161.21 (39.79%)

STA Analyst Target

USD 155.80 (35.10%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

Alexion Pharmaceuticals Inc is a biopharmaceutical company engaged in serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.

Company Website : http://www.alexionpharm.com

Currency: USD

Country : USA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-08-15 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
AMGN Amgen Inc.

-0.50 (-0.26%)

 USD 126.39B
GILD Gilead Sciences Inc.

-2.47 (-3.19%)

 USD 97.02B
BIIB Biogen Inc.

-2.91 (-0.85%)

 USD 68.64B
CELG Celgene Corporation

-3.44 (-3.71%)

 USD 62.79B
SHPG Shire plc

-0.80 (-0.47%)

 USD 51.31B
VRTX Vertex Pharmaceuticals Incorpo..

-2.93 (-1.67%)

 USD 44.21B
REGN Regeneron Pharmaceuticals Inc.

-4.36 (-1.19%)

 USD 39.10B
BMRN BioMarin Pharmaceutical Inc.

-1.33 (-1.29%)

 USD 18.08B
INCY Incyte Corporation

+0.42 (+0.63%)

 USD 14.22B
GRFS Grifols S.A.

-0.71 (-3.43%)

 USD 13.66B

ETFs Containing ALXN

PBE Invesco Dynamic Biotech &.. 4.93 % 0.59 %

-0.95 (-1.64%)

 USD 0.28B
FMDG Fieldstone Merlin Dynamic.. 4.13 % 0.00 %

N/A

 N/A
IBB iShares Nasdaq Biotechnol.. 3.67 % 0.47 %

-1.83 (-1.56%)

 USD 9.18B
BBP Virtus LifeSci Biotech Pr.. 2.61 % 0.84 %

-0.81 (-1.86%)

 USD 0.03B
RYH Invesco S&P 500 Equal Wei.. 1.72 % 0.40 %

-1.33 (-0.68%)

 USD 0.66B
QQXT First Trust NASDAQ-100 Ex.. 1.70 % 0.60 %

-0.74 (-1.42%)

 USD 0.09B
XBI SPDR Series Trust S&P Bio.. 1.48 % 0.35 %

-1.81 (-1.91%)

 USD 5.28B
PEXL Pacer US Export Leaders 1.13 % 0.00 %

N/A

 USD 2.52M
QQEW First Trust NASDAQ-100 Eq.. 1.10 % 0.60 %

-0.79 (-1.26%)

 USD 0.57B
QQQE Direxion NASDAQ-100 Equal.. 1.06 % 0.35 %

-0.62 (-1.33%)

 USD 0.19B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.57% 55% F 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.57% 55% F 37% F
Trailing 12 Months  
Capital Gain -14.71% 44% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.71% 43% F 21% F
Trailing 5 Years  
Capital Gain 8.64% 59% F 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.64% 58% F 34% F
Average Annual (5 Year Horizon)  
Capital Gain -0.62% 40% F 29% F
Dividend Return -0.62% 39% F 25% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 23.74% 86% B 55% F
Risk Adjusted Return -2.62% 40% F 26% F
Market Capitalization 26.24B 98% A+ 98% A+

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
(Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 71.80 100% A+ 98% A+
Price/Book Ratio 2.82 60% D- 40% F
Price / Cash Flow Ratio 13.35 2% F 6% F
Price/Free Cash Flow Ratio 147.85 1% F 3% F
Management Effectiveness  
Return on Equity -1.12% 81% B- 41% F
Return on Invested Capital 8.70% 86% B 67% D+
Return on Assets -0.73% 90% A- 43% F
Debt to Equity Ratio 35.50% 36% F 55% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

ALXN:NGS-Alexion Pharmaceuticals Inc.

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 115.32

Change

-4.36 (-3.64)%

Market Cap

USD 25.70B

Volume

1.81M

Yahoo Analyst Target

USD 161.21 (39.79%)

STA Analyst Target

USD 155.80 (35.10%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

Values as of: 2018-08-15